Healthcare >> CEO Interviews >> April 15, 2005
MICHAEL T. SEMBER President & CEO DOR BioPharma, Inc. Mr. Sember brings
to DOR over 30 years of broad experience working with both public and
private pharmaceutical and biotech companies in the US and Europe. Mr.
Sember has an extensive business development, operating and financial
background which includes nearly 100 licensing transactions and several
corporate acquisitions. Most of Mr. Sember's professional career was
spent in senior executive positions with Marion Laboratories and Elan
Corporation, plc. While at Elan, Mr. Sember held the position of
Executive Vice President of Business Development and was directly
responsible for building a strategic alliance portfolio, which included
over 30 products in clinical development across several therapeutic
areas including neurology, oncology, and pain management. During this
period, he generated close to $900 million in licensing revenue during
the development of the alliance portfolio. He was also responsible for
building and managing an investment portfolio valued at approximately
$1.25 billion during his tenure at Elan. Mr. Sember has served on the
Boards of eight public and private biotech companies and on the Advisory
Boards of several venture capital firms. Most recently, Mr. Sember has
served as Managing Director of EGB Advisors LLC, a San Francisco based
consulting firm and biotech incubator. Profile
EVAN MYRIANTHOPOULOS is CFO of DOR BioPharma, Inc. Evan is also
currently the President and founder of CVL Advisors, LLC, a financial
consulting firm specializing in the biotechnology sector. Prior to
founding CVL Advisors, Mr. Myrianthopoulos was a co-founder of Discovery
Laboratories, Inc., a public specialty pharmaceutical company developing
respiratory therapies. While at Discovery, Mr. Myrianthopoulos held the
positions of Chief Financial Officer and Vice President of Finance where
he was responsible for raising approximately $55 million in four private
placements. He also negotiated and managed Discovery's merger with Ansan
Pharmaceuticals and Acute Therapeutics. Prior to co-founding Discovery,
Mr. Myrianthopoulos was a Technology Associate at Paramount Capital
Investments, L.L.C., a New York City based biotechnology venture capital
and investment banking firm. Prior to joining Paramount Capital, Mr.
Myrianthopoulos was a managing partner of S + M Capital Management, a
hedge fund which specialized in syndicated stock offerings and also
engaging in arbitrage of municipal and mortgage bonds. Prior to that,
Mr. Myrianthopoulos held senior positions in the treasury department at
the National Australia Bank where he was employed as a spot and
derivatives currency trader. Mr. Myrianthopoulos holds a B.S. in
Economics and Psychology from Emory University. Profile
a picture of the things you're doing at the present time?
Mr. Myrianthopoulos: My name is Evan Myrianthopoulos and I'm
